<DOC>
	<DOCNO>NCT01377532</DOCNO>
	<brief_summary>This compassionate use protocol allow palliative therapy patient malignant pheochromocytoma paragangliomas .</brief_summary>
	<brief_title>Compassionate Use 131I-MIBG Patients With Malignant Pheochromocytoma</brief_title>
	<detailed_description>Pheochromocytomas ( PHEO ) paragangliomas ( PGL ) rare tumor , incidence 2-8 case per million annually . These tumor develop child adult . About 15-20 % metastasize . Chemotherapy tumor usually consist combination cyclophosphamide , vincristine , dacarbazine deliver two day repeat every 3 week . Such combined chemotherapy ineffective majority patient metastatic PHEO/PGL . A patient malignant PHEO experience remission sunitinib , drug may produce severe toxicity experience drug limit . Those patient experience remission chemotherapy must continue indefinitely stay remission . However , patient experience severe side effect chemotherapy ( marrow suppression , neuropathy , etc ) chemotherapy must discontinue . Thus , chemotherapy either ineffective intolerable vast majority patient metastatic PHEO/PGL .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Diagnosis : Refractory relapse PHEO/PGL original diagnosis base tumor histopathology find PHEO/PGL tumor cell bone marrow . The diagnosis may also base upon presence high plasma fractionate metanephrines high urine catecholamines/metanephrines diagnostic MIBG uptake . Age : &gt; 2 year able cooperate radiation safety restriction therapy period . Disease status : It must determine either PHEO/PGL tumor amenable safe surgical resection metastatic . Disease evaluable MIBG scan must present within 6 week study entry subsequent intervening therapy . Life Expectancy : great 3 month . Lanksy Karnofsky Performance Status : 70 % high . Prior Therapy : Patients may enter study without therapy recurrent tumor . Patients may treat chemotherapy radiation therapy . Patients may also treat fail respond standard chemotherapy radiation therapy . Patients must fully recover toxic effect prior therapy . At least 2 week elapse since antitumor therapy patient must meet hematologic criterion . Three month elapse case complete radiation follow field : total craniospinal , total abdominal , whole lung , total body irradiation ) . Cytokine therapy ( eg GCSF , GMCSF , IL6 , erythropoietin ) must discontinue minimum 24 hour prior MIBG therapy . Prior 131IMIBG therapy allow &gt; 8 week previous treatment . Cumulative lifetime dose 131IMIBG , include plan treatment , exceed 36 mCi/kg . Liver function : bilirubin &lt; 2x upper limit normal ( ULN ) . Exception : Gilbert syndrome ) ; AST &lt; 10x ULN . Kidney function : Creatinine = &lt; 2x ULN . Hematopoietic Criteria Patients must adequate hematopoietic function ( without transfusion ) : ANC &gt; 750 x 10E9/L ; Platelets &gt; 50 x 10E9/L stem cell available ; stem cell available , patient independent platelet transfusion platelet count least 20 x 10E9/L . Hemoglobin &gt; 10g/dl time treatment ( transfusion allow ) . Patients granulocytopenia and/or thrombocytopenia due tumor metastatic bone marrow may eligible discussion Dr. Fitzgerald designee . Normal lung function manifest dyspnea rest exercise intolerance , oxygen requirement . No clinically significant cardiac dysfunction , normal EKG EJ &gt; 50 % Patients disease major organ system would compromise ability withstand therapy . Any significant organ impairment discuss Study Chair Vice Chair prior patient entry . Patients proteinuria absence urinary infection 4 week prior plan treatment date . Because teratogenic potential study medication , patient pregnant breast feeding allow . Patients childbearing potential must practice effective method birth control participate study , avoid possible pregnancy . Patients hemodialysis . Patients active infection meet grade 34 toxicity criterion .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Pheochromocytoma</keyword>
	<keyword>Paraganglioma</keyword>
	<keyword>MIBG</keyword>
	<keyword>131I-MIBG</keyword>
	<keyword>Resistant</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Treatment</keyword>
	<keyword>UCSF</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adult</keyword>
	<keyword>Oncology</keyword>
</DOC>